Table 1.
Patients' pretreatment regimens.
| Pat ID | Age | Sex | Disease | Lines of treatment prior to leukoapheresis | Allogeneic HCT |
|---|---|---|---|---|---|
| T01 | 27 | M | ALL | PETHEMA 2011, blinatumomab, radiotherapy | Yes (+ DLI) |
| T02 | 25 | M | PMLBCL | R-CHOP, R-ESHAP, autologous HCT, radiotherapy, brentuximab, GSK525762, nivolumab | No |
| T03 | 7 | F | ALL | SEHOP 2013, SEHOP 2016, inotuzumab, methotrexate + cyclophosphamide + anthracyclins + prednisone | Yes (+ DLI) |
| T04 | 19 | F | PMLBCL | R-CHOP, R-ESHAP, autologous HCT, radiotherapy, BURKIMAB, Gemcitabine + vinorelbine + procarbacine | No |
| T05 | 51 | M | DLBCL | BURKIMAB, autologous HCT, cyclophosphamide + prednisone, GSK525762, methotrexate, cyclophosphamide | No |
| T06 | 20 | F | ALL | PETHEMA 2011, PETHEMA 2008 | Yes |
| T07 | 19 | M | ALL | PETHEMA 2011, FLAG-Ida | Yes |
| T08 | 53 | F | CLL | FCR, BR, ibrutinib, venetoclax, obinutuzumab, idelalisib | No |
| T09 | 8 | M | ALL | SEHOP 2008, SEHOP 2013 | No |
| T13 | 20 | M | ALL | GRAAL 2003, FLAG-Ida, blinatumomab | Yes (x2) |
| T11 | 34 | F | ALL | PETHEMA 2011, Hyper-CVAD, inotuzumab | Yes |
| T12 | 3 | F | ALL | SEHOP 2013, SEHOP 2016, vincristine + prednisone | Yes |
| T14 | 27 | M | ALL | PETHEMA 2008, FLAG-Ida, PETHEMA 2011 | Yes |
| T15 | 30 | M | ALL | PETHEMA 2011, FLAG-Ida, FLAG-Ida + blinatumomab, FLAG-Ida, inotuzumab | Yes (x2 + DLI) |
| T16 | 10 | M | ALL | SEHOP 2013 | Yes |
| T17 | 23 | M | ALL | PETHEMA 2011, FLAG-Ida, PETHEMA 2008, BFM-90, inotuzumab | Yes |
| T19 | 9 | F | ALL | PETHEMA, SEHOP 2015, radiotherapy | No |
| T20 | 35 | M | ALL | PETHEMA 2011, FLAG-Ida, PETHEMA 2011, methotrexate + vincristine + dexamethasone | Yes |
| T21 | 13 | F | ALL | SEHOP 2013, SEHOP 2016, prednisone | Yes |
| T22 | 29 | M | ALL | PETHEMA 2008, dasatinib, FLAG-Ida + ponatinib, FCR | Yes |
| T24 | 19 | M | ALL | PETHEMA 2011, FLAG-Ida | No |
| T25 | 47 | F | ALL | PETHEMA 2011, FLAG-Ida, PETHEMA 2011 | Yes |
| T26 | 8 | F | ALL | SEHOP | Yes |
| T27 | 22 | M | ALL | PETHEMA 2008, FLAG-Ida, PETHEMA 2011 | No |
| T30 | 31 | M | ALL | PETHEMA 2008, blinatumomab | Yes (+DLI) |
| T32 | 23 | M | ALL | PETHEMA 2008, PETHEMA 2011, vindesine + prednisone, inotuzumab | Yes (x2) |
| T34 | 45 | F | DLBCL | R-CHOP, R-ESHAP, BURKIMAB, radiotherapy | No |
ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; PMLBCL, primary mediastinal large B-cell lymphoma; CLL, chronic lymphocytic leukemia; DLI, donor lymphocyte infusion; HCT, hematopoietic cell transplantation; FCR, fludarabina + cyclophosphamide + rituximab; BR, bendamustina + rituximab; FLAG-Ida, fludarabina + cytarabine + idarubicin + G-CSF; PETHEMA, Spanish Program of Treatments in Hematology; SEHOP, Spanish Society of Pediatric Hematology & Oncology; GRAAL, Group for Research on Adult Acute Lymphoblastic Leukemia.